An integrated approach in the diagnosis of smoking-related interstitial lung diseases by A. Caminati et al.
REVIEW
An integrated approach in the diagnosis of
smoking-related interstitial lung diseases
Antonella Caminati*, Alberto Cavazza#, Nicola Sverzellati" and Sergio Harari*
ABSTRACT: Cigarette smoke consists of several chemical compounds with a variety of effects in
many organs. In the lung, apart being the main cause of chronic obstructive pulmonary disease,
carcinoma and idiopathic spontaneous pneumothorax, tobacco smoke is associated with
interstitial lung diseases (ILDs), including respiratory bronchiolitis-associated ILD (RB-ILD),
desquamative interstitial pneumonia (DIP), pulmonary Langerhans’ cell histiocytosis (PLCH),
idiopathic pulmonary fibrosis, acute eosinophilic pneumonia, ILD in rheumatoid arthritis and
pulmonary haemorrhage in Goodpasture syndrome.
This review will focus on the diseases with a stronger epidemiological association with tobacco
smoke, namely RB-ILD, DIP and PLCH. Although the exact pathogenetic evidence linking smoking
with these disorders is still not completely understood, there is growing evidence that tobacco
smoke targets the terminal or respiratory bronchioles in these diseases, and the differences are
reflective of the degree of severity of small airway and parenchymal reaction to the smoke
exposure.
Despite considerable clinical, radiological and histological overlap between RB-ILD, DIP and
PLCH, it is useful to retain the separate classifications for prognostic and therapeutic implications.
KEYWORDS: Desquamative interstitial pneumonia, interstitial lung diseases, Langerhans’ cell
histiocytosis, respiratory bronchiolitis, smoking
T
he influence of tobacco smoke on human
health is still an important problem in the
developed world. Complex inflammatory
processes and changes in the immune system are
crucial in the pathogenesis of smoking-related
disorders, such as chronic obstructive pulmonary
disease (COPD), emphysema, lung cancer and
atherosclerosis. The term asymptomatic smoker
implies a healthy smoker, i.e. without clinical
symptoms of chronic bronchitis and with normal
values of pulmonary function tests, which is
differentiated from a smoker with signs of COPD
or interstitial diseases. However, the line of divi-
sion is difficult to define because of the possibility
of asymptomatic bronchiolitis [1]. The role of
tobacco smoke in the pathological processes of
small airways is well documented [2, 3]. The
cause–effect relationship between a history of
cigarette smoking and interstitial diseases is a
more recent acquisition. Respiratory bronchiolitis
(RB) is present pathologically in most smokers, but
very few of them experience symptoms. RB is
characterised by airway-centred accumulations of
macrophages containing fine, granular yellow-
brown cytoplasmic pigments (‘‘smoker’s macro-
phages’’) within distal bronchioles, alveolar ducts
and adjacent alveolar spaces. Cytoplasmic pig-
mentation is variable and correlates with the num-
bers of pack years smoked [4]. RB represents a
highly specific physiological response to smoking.
RB-associated interstitial lung disease (ILD) is the
term used to describe smokers who become symp-
tomatic secondary to RB [5]. RB-ILD is an un-
common ILD that occurs in a small proportion of
smokers [5]. Because of the significant overlap in
clinical, radiological and histological features
between RB-ILD and desquamative interstitial
pneumonia (DIP), these entities are considered a
pathomorphologic continuum, representing dif-
ferent degrees of severity of the same disease
process [6–10]. However, there are prognostic
reasons for continuing to separate RB-ILD from
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DIP when possible. The mortality of patients with DIP is 6–30%,
while only rarely have patients with RB-ILD been reported to
die of their disease [5, 11–15]. Additionally, patients with DIP
may develop acute exacerbations [16–18]. DIP is one of the rarest
idiopathic interstitial pneumonias and is characterised by the
diffuse accumulation of large numbers of pigmented macro-
phages in alveolar spaces associated with interstitial inflam-
mation and/or fibrosis [19]. In the majority of cases, DIP is
considered to be a smoking or dust inhalation-related intersti-
tial pneumonia. The association of organ-specific immunolog-
ical diseases and elevated antinuclear antibody, observed in
some cases, and bronchoalveolar lavage (BAL) eosinophilia/
neutrophilia in DIP suggest that the pathogenesis may be
immunologically mediated [13, 20]. Pulmonary Langerhans’ cell
histiocytosis (PLCH) is a non-neoplastic reactive process to
cigarette smoke. It is characterised by multiple stellate cellular
nodules centred around, or adjacent to, small airways. Over
time, these lesions show increasing amounts of stellate fibrosis
with cyst formation [21, 22]. The cystic cavities represent the
highly distorted bronchiolar lumen resulting from the destruc-
tion of the airway walls by Langerhans’ cell (LC) granuloma
[23]. The relationship of smoking with RB-ILD, DIP and PLCH
has been largely established on the basis of epidemiological
evidence. These diseases are correctly considered as distinct and
separate conditions in the classification of ILDs, but these three
entities share a number of clinical, radiological and pathological
features, suggesting that they represent a spectrum of patterns of
ILDs occurring in predisposed individuals who smoke. The
association of pulmonary emphysema with non-specific inter-
stitial pneumonia (NSIP) provides support for cigarette smoking
as a pathogenetic factor in a subset of NSIP patients in recent
studies [24–27]. Acute eosinophilic pneumonia is a dramatic res-
ponse to recent onset smoking in a small number of individuals
[28]. Recently, a new entity has been highlighted, combined pul-
monary fibrosis and emphysema (CPFE) [29]. Not just a distinct
phenotype of idiopathic pulmonary fibrosis (IPF), the syndrome
of CPFE is characterised by the association of distinct features,
including: tobacco smoking; severe dyspnoea; unexpected near
normal lung volumes; severely impaired diffusing capacity of
the lung for carbon monoxide (DL,CO); hypoxaemia at exercise;
characteristic radiological features (centrilobular and/or para-
septal emphysema, and diffuse interstitial aspects suggestive of
pulmonary fibrosis at the lower lobes); frequent association with
pulmonary hypertension; and poor prognosis [30–32]. This
review will focus on the diseases with a stronger epidemiolo-
gical association with smoke, namely RB-ILD, DIP and PLCH.
HISTOLOGICAL–RADIOLOGICAL CORRELATIONS
RB and other abnormalities
From the pathologist’s perspective, the most characteristic
effect of tobacco smoke on lung parenchyma is RB, consisting
of the presence of bronchioles and peribronchiolar alveoli of
finely pigmented, iron-containing (smoker’s) macrophages in
the lumen (fig. 1a) [4, 33, 34]. The degree of pigmentation is
related to the number of pack-years smoked [4]. In heavy
smokers, particularly marijuana smokers [35], the pigment can
become coarser and the distinction with haemosiderin due to
chronic haemorrhage may be difficult to identify on purely
histological grounds, therefore, clinical evidence is required.
The changes are patchy at low magnification, generally with
a striking bronchiolocentric distribution (fig. 1b); however,
smoker’s macrophages may variably extend to the peripheral
alveoli, occasionally involving the entire lobule (fig. 1c). The
amount of pigmented macrophage accumulation within
respiratory bronchioles observed histologically correlates with
the profusion of centrilobular nodules on high-resolution com-
puted tomography (HRCT) [36]. Such nodules are poorly
defined and separated from the pleural surfaces, fissures and
interlobular septa by several millimetres (fig. 1d) [37]. The
intensity of macrophage accumulation in the alveoli and
alveolar ducts is linked to the extent of ground-glass attenuation
on HRCT [36]. However, ground-glass opacities do not ex-
clusively correspond to macrophage accumulation at histology
as they may also be caused by mild interstitial inflammation
and/or fibrosis [36].
Frequently, smoker’s macrophages are associated with subtle
histological features of chronic bronchiolitis, including mild
lymphocytic inflammation and mild fibrosis of the bronchiolar
wall and surrounding alveolar septa; sometimes with rigidity
and distortion of the bronchiolar lumen, bronchioloectasia and
mucostasis. Although these changes can be prominent enough
to be histologically indistinguishable from constrictive bronch-
iolitis, they generally only have minor clinical consequences in
the form of mild airflow obstruction. It is conceivable assuming
that scattered lobules of reduced attenuation on HRCT, con-
firmed as lobular air trapping on expiratory computed tomo-
graphy scanning, may be correlated with the remodelling of
both membranous and respiratory bronchioli. However, air
trapping is not as extensive on HRCT as is observed in other
mixed interstitial and small airways diseases [38]. Air trapping
may be accompanied by a slight thickening of the larger (e.g.
subsegmental) intralobar airways, possibly reflecting changes
of chronic bronchitis [39].
RB is very frequent in smokers, and probably is the most
sensitive and specific histological marker of tobacco smoke. In a
study on 156 surgical specimens [4], RB was found in all 83
current smokers and in only two out of 24 never-smokers;
however, the smoking history was controversial in both groups.
Interestingly, RB was also present in ,50% of ex-smokers,
sometimes persisting many years after smoking cessation. Of
the 109 patients who had RB, RB was the cause of an ILD in only
two (RB-ILD and DIP in one patient each). In other words, RB is
generally a histologically incidental finding in smokers (as the
biopsy is obtained for another reason, for example, a carci-
noma), and only rarely does RB cause an ILD. Although patients
with ILDs have, in general, more severe histological alterations,
histology alone is unable to predict the presence of ILD in a
single case. Similarly, RB and RB-ILD cannot be distinguished
solely from the nature of HRCT abnormalities, as there is no
arbitrary cut-off in HRCT disease extent at which RB becomes
RB-ILD. However, the extent of disease on HRCT images should
be taken into account when reaching the decision that clinically
significant ILD (i.e. RB-ILD) is present [40]. The distinction
between RB and RB-ILD varies greatly in the literature.
Recently, CHURG et al. [41] proposed a strict definition of RB-
ILD, which we concur with; therefore, following this definition,
RB-ILD should be restricted to smokers with restrictive or mixed
obstructive and restrictive functional abnormalities, with a marked
decrease in diffusing capacity with minimal airflow obstruction, or
with ground-glass opacities/centrilobular nodules plus reticula-
tion at HRCT, and no other lesions besides RB on biopsy.
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Once the clinician has established the presence of an ILD due
to RB, the distinction between RB-ILD and DIP is mostly based
on the extension of smoker’s macrophages: in RB-ILD the latter
are restricted to the centrilobular area, whereas in DIP they
involve the lobule more diffusely. Moreover, interstitial fibro-
sis (see below), lymphoid follicles, giant cells and eosinophils
are more frequent in DIP than RB-ILD [13, 18]. In some patients
with DIP the number of eosinophils (both in tissue and BAL) is
high enough to raise concern about the possibility of chronic
eosinophilic pneumonia (fig. 1e). However, the limits between
RB-ILD and DIP are blurred and in practice the distinction
can be difficult and, in some cases, is probably quite arbitrary;
depending on sampling, the degree of alveolar filling from
smoker’s macrophages can vary from one lobule to another.
Due to this, some authors suggest that RB-ILD and DIP should
be grouped into one category [10]. However, we share the opi-
nion of the majority that they should be classified separately
whenever possible because of the differences in clinical
presentation and prognosis, acknowledging that in rare cases
the distinction is impossible [40]. On HRCT, RB-ILD differs
from DIP in that ground-glass attenuation of RB-ILD is usually
less extensive, more patchy and more poorly defined. A peri-
pheral, sub-pleural and basal predominance of ground-glass
opacity reflecting either accumulation of intra-alveolar macro-
phages or septal thickening is most commonly seen in DIP [7].
Although HRCT features can be useful in identifying probable
DIP rather than RB-ILD, the overlapping features on HRCT
scans in some cases and the occasional histological coexistence
of the two entities further emphasise the need for an integrated
clinical, radiological and pathological approach to secure a
correct diagnosis [42].
Fibrosis and emphysema
The tendency for cigarette smokers to develop limited or
extensive interstitial fibrosis is increasingly being reported by
radiological and histological studies. In an accurate histological
study on surgical resections performed for lung cancer,
KAWABATA et al. [43] found foci of fibrosis with usual interstitial
pneumonia (UIP) pattern in the non-neoplastic lung in 21.3%
of smokers (125 out of 587), frequently without overt clinical
features of ILD (only 49 patients had a pre-operative clinical
diagnosis of IPF). No long-term follow-up was provided so the
significance of this finding is unknown but, interestingly, all
the patients who developed acute respiratory failure following
surgery had UIP foci at histology. It is worth noting that, in a
very different clinical setting (surgical biopsy performed
because of ILD), the histological diagnosis of early UIP arising
in the background of chronic smoking-related abnormalities is
occasionally difficult.
A recent study by WASHKO et al. [44], showed that ,5% of a
large cohort of smokers (41% met the criteria for COPD)
displayed minimal sub-pleural interstitial abnormalities on
HRCT. However, extensive interstitial abnormalities were
found in only 0.8% of the study population [44]. Another
recent study showed that the prevalence of extensive inter-
stitial abnormalities among HRCT examinations of smokers
recruited by a lung cancer screening trial was 4%, with a UIP-
like pattern and NSIP-like pattern reported in 0.3 and 3.7% of
the cases, respectively. Intriguingly, the interstitial abnormal-
ities increased in extent among persistent current smokers,
whereas they decreased in quitters [45]. In both studies,
smokers with sub-pleural changes were more likely than those
a) b)
d) e)
c)
FIGURE 1. a) Respiratory bronchiolitis: the intra-alveolar accumulation of finely pigmented macrophages (smoker’s macrophages) (haematoxylin and eosin, 4006).
Generally smoker’s macrophages have a strict bronchiolocentric distribution (b; haematoxylin and eosin 406), but occasionally they involve the entire lobule (c; haematoxylin
and eosin, 206). d) Respiratory bronchiolitis in a 63-yr-old heavy smoker who was asymptomatic at the time of computed tomography. The high-resolution computed
tomography image shows bilateral poorly defined centrilobular nodules in the upper lobes. e) Occasionally, particularly in desquamative interstitial pneumonia, a relatively
large number of eosinophils are present and the limits with chronic eosinophilic pneumonia are sometimes blurred (haematoxylin and eosin, 2006).
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without these abnormalities to be older. An intriguing possibi-
lity is that the lung abnormalities related to cigarette smoking
are analogous to those seen in elderly nonsmokers, suggesting
that cigarette smoking may have a premature ageing effect
on the lungs [38, 46]. Indirect evidence for the idea of the
development of fibrotic elements as part of the ageing process
has come from a study by COPLEY et al. [46], in which a basal sub-
pleural reticular pattern was identified in 60% of HRCTs of
healthy individuals aged .75 yrs but in none of those aged
,55 yrs [46].
Although emphysema is classically defined as permanent
airspace enlargement without ‘‘obvious’’ (macroscopic) fibrosis
[47, 48], in reality some microscopic fibrosis is quite frequent in
centrilobular and, particularly paraseptal emphysema, and
often quite prominent [49, 50]. KATZENSTEIN et al. [51] identified
fibrosis involving .25% of slides in 20 (60%) extensively
sampled lobectomy specimens from smokers. Importantly, the
authors noted that fibrosis, although sometimes histologically
quite dramatic, did not produce clear clinical abnormalities,
being an incidental finding in smokers undergoing operations
for other reasons. Reported in the literature with terms (RB-ILD
with fibrosis [24], airspace enlargement with fibrosis [43],
smoking-related interstitial fibrosis [51]), fibrosis in this set-
ting has a typical dense, amyloid-like character and is more
prominent in sub-pleural and peribronchiolar parenchyma,
where it frequently surrounds emphysematous spaces (fig. 2a
and b). Sometimes large emphysematous holes are criss-crossed
by bands of fibrosis. Fibrosis that is not associated with
emphysema can also occur.
Limited fibrosis combined with pulmonary emphysema may be
too fine to be seen on HRCT images. However, mild ground-
glass opacification and fine intralobular reticulation may be
observed in confined emphysematous areas on HRCT images
(fig. 2c). Future investigations are needed to assess this type of
HRCT pattern. Nonetheless, it has been shown that diffuse
fibrosing interstitial pneumonia, most commonly UIP, occurs
in patients with emphysema. COTTIN et al. [30] have proposed
that such cases fall under the subheading of CPFE, which may
have distinctive clinical implications (e.g. increased incidence of
pulmonary hypertension as compared to similar forms without
emphysema). Differentiation of NSIP from UIP by HRCT
becomes more difficult in cigarette smokers with emphysema.
In a study of 54 patients with NSIP and 42 patients with UIP, the
computed tomography diagnosis was correct in 44% of readings
in those with concurrent emphysema, compared with 68% in
those without concurrent emphysema [52].
In some smokers with ILD, fibrosis is so prominent that it
makes the differential diagnosis between DIP and fibrotic NSIP
difficult, both histologically and radiologically. Moreover,
some authors suggest that DIP can evolve into NSIP [8], and
that some cases of fibrotic NSIP can be related to tobacco
smoke. In a retrospective HRCT study, MARTEN et al. [26]
compared the prevalence and extent of emphysema in smokers
with NSIP versus smokers with COPD and ‘‘healthy’’ smokers.
The authors reported emphysema in a striking majority of
NSIP cases (77.8%) and COPD cases (73.5%) but not so in the
‘‘healthy’’ smokers (17.5%). The high prevalence of emphy-
sema in the NSIP patients, which did not differ from the COPD
controls, provided indirect support for a smoking pathogenetic
hypothesis in some NSIP patients. Although compelling, these
hypotheses are as yet unproven. In our practice we try to
separate DIP and fibrotic NSIP whenever possible, particularly
because the prognosis of DIP appears to be better than fibrotic
NSIP, again acknowledging that, in occasional cases, the
distinction is difficult and probably arbitrary.
Increase in LCs
Another common effect of smoking is the increase in the number
of LCs, which are detectable in lung tissue and BAL. LCs are
characteristic both on morphology (moderate amount of pale
cytoplasm, deeply infolded nuclei) and immunophenotype
(positivity for S-100 protein, CD1a and Langerin [53]). By
definition, in PLCH LCs form clusters, but the limits between
PLCH and a simple increase in LCs in a smoker are conventional
and sometimes blurred. PLCH occurs when LCs accumulate in
the bronchiolar wall (fig. 3a) and disperse into the surrounding
alveolar septa, forming multiple stellate nodules centred on
small airways (fig. 3b) [54, 55]. On HRCT, nodules are usually
,5 mm in diameter, and have a peribronchiolar and centrilob-
ular distribution. The extent of nodular lesions on HRCT is
strongly correlated with the density of lesions in the bioptic
specimens [56].
Together with LCs, these cellular nodules frequently incorporate
a variable number of eosinophils and smoker’s macrophages,
both in surrounding alveolar spaces and in the interstitium. An
associated RB is almost universal and sometimes extensive,
a) b) c)
FIGURE 2. Smoking-related fibrosis with dense acellular fibrosis that frequently surrounds cystic emphysematous spaces, both in a) centrilobular (haematoxylin and
eosin, 406) and b) sub-pleural parenchyma (haematoxylin and eosin, 206). c) Specific smoking-related interstitial abnormalities in a heavy smoker with dyspnoea. A high-
resolution computed tomography image showing mild ground-glass opacity and reticulation circumscribing emphysematous areas.
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being visible on computed tomography scans as ground-glass
opacities (fig. 3c) [42]. Over time, the centre of the nodules
becomes fibrotic and irregular cavities develop in some of the
nodules, leading to the classical histological features of mature
PLCH, multiple stellate nodules, some of which are cavitated
and surrounded by normal lung (fig. 3d). HRCT images closely
mirror the pathologic findings, showing some of the nodules that
cavitate. In more advanced stages, the HRCT appearance is
characterised by a cystic-nodular pattern mostly involving the
upper lobes, which usually permits a confident diagnosis (fig. 3e).
Nodules and cysts can occur independently of each other, but in
the majority of patients they are found concomitantly. However,
end-stage PLCH, when the distribution characteristics are less
obvious, may be difficult to distinguish radiologically from
other cystic lung diseases, such as lymphangioleiomyomatosis
(in females), lymphocytic interstitial pneumonia and, above all,
emphysema [57].
The outcome of these lesions varies from case to case, probably
depending on the abstinence from smoking and from individual
predisposition. In many cases the nodules reabsorb completely
or form small bronchiolocentric scars with paracicatricial
emphysema (fig. 3f). It is reasonable to assume that some cases
of centrilobular emphysema with fibrosis are in reality examples
of healed PLCH. Recent observations show that even cystic
lesions in PLCH, as observed on HRCT, harbour active granu-
lomas on histopathology regardless of their wall thickness, and
may show improvement on serial computed tomography con-
trols [58]. In a minority of patients progressive fibrosis develops;
the stellate shape of the scars, their bronchiolocentric distribu-
tion with a prevalence in the upper lobes, and the absence/
paucity of fibroblastic foci are characteristic of chronic PLCH
and are sufficient for a firm diagnosis in the majority of the
cases, even in the absence of residual LCs. Occasionally, how-
ever, the histological differential diagnosis with UIP is difficult
and requires a strict correlation with clinical–radiological
findings. As for RB, emphysema and fibrosis, PLCH can also
be a histological incidental finding in the lung specimen
removed for another disease, for example carcinoma.
Summary of histological and radiological findings
As we have seen, tobacco smoke can cause many histological
and radiological abnormalities (table 1). These abnormalities
can be variably combined, creating a significant overlap among
the different entities. Moreover, they frequently provide a
backdrop for other diseases that are more clinically relevant.
For these reasons, in order to establish the significance of
histological and radiological findings a close correlation with
clinical data is mandatory.
Clinical and functional aspects in RB-ILD and DIP
Patients with RB-ILD or DIP are usually 30–40 yrs of age and
have an average smoking history of 30 pack-yrs [7, 11]; males
are affected approximately twice as often as females [59, 60].
Symptoms and clinical aspects in both these diseases are non-
specific. Slowly progressive exertional dyspnoea and cough
(which may be not productive) are the most frequent symptoms
of presentation [5, 6, 11, 40]. The presence of symptoms, mainly
a) b) c)
d) e) f)
FIGURE 3. a) Pulmonary Langerhans’ cell histiocytosis (PLCH) is characterised by an increased number of CD1a+ Langerhans’ cells in the bronchiolar wall (2006). b) In
the early/active phase of PLCH stellate cellular nodules with a bronchiolocentric distribution can be seen (haematoxylin and eosin, 106). c) A stellate fibrotic nodule
suggestive of healed PLCH is present on the left and is associated with an extensive accumulation of smoker’s macrophages (haematoxylin and eosin, 206). d) Classical
example of PLCH in its mature phase consisting of multiple bronchiolocentric cellular nodules, some of which are fibrotic and irregularly cavitated (haematoxylin and eosin,
106). e) A high-resolution computed tomography image at the level of the upper lobes showing numerous irregularly marginated bilateral nodules; a few cysts are visible.
f) Chronic PLCH showing stellate scars with paracicatricial emphysema (haematoxylin and eosin, 406).
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in RB-ILD, is not consistent; the disease may be diagnosed in
asymptomatic patients with functional impairment, end-inspira-
tory crackles on pulmonary examination and chest radiograph or
HRCT abnormalities [40]. Bilateral basal inspiratory crackles are
frequent (,50–60% of DIP cases, rarer in RB-ILD), whereas
clubbing is rare [6].
Despite the bronchiolocentric nature of disease in RB-ILD, both
restrictive and obstructive alterations have been described [5, 6],
with a mixed, predominantly restrictive, ventilator defect, usually
associated with a mild-to-moderate reduction inDL,CO, the most
frequent finding [5, 6]. There is no complete correspondence
between histological and functional severity of disease; some
patients with near normal pulmonary functional evaluation
have moderately extensive fibrotic change radiating from the
bronchioles at lung biopsy [4]. However, this is likely to reflect
the problem of sampling error [40, 61], with histological seve-
rity at biopsy not representative of the severity of the lung
involvement. In DIP, the functional abnormality is predomi-
nantly restrictive with the DL,CO reduction a useful guide to the
underlying severity of the disease. An important confounder in
the interpretation of functional impairment in both RB-ILD and
DIP is the frequent concomitant presence of emphysema. In these
cases, the presence of emphysema may justify a predominantly
obstructive defect on pulmonary function tests. A mild obstruc-
tive alteration may be due to concomitant chronic bronchiolitis. In
other cases the co-existence of emphysema and fibrotic changes
may give rise to paradoxically normal lung volumes associated
with a disproportionate reduction in DL,CO [5, 6].
Clinical and functional aspects in PLCH
PLCH is a rare disease [62]. The classification of histiocytic
disorders has been simplified and is based on the presence of
single or multi-organ involvement [63]. In the latter case, lung
disease is most commonly found in children and is not
associated with smoking. The significant clinical and epide-
miological differences between the pulmonary and systemic
forms of the disease suggest that although the pivotal cell may
be the same (LC), the pathogenetic pathways are different
[63–67]. More than 90% of patients with isolated PLCH are cur-
rent or former smokers [63–67]. Although the proposed patho-
genesis of PLCH revolves around an immune response involving
locally recruited LCs and other inflammatory/immune cells,
the trigger for cellular proliferation appears to be an inhaled
antigen, probably residing in tobacco smoke [67, 68]. This
hypothesis is supported by the peribronchiolar distribution of
the lesions in this disease. LCs are differentiated antigen-
presenting cells of monocyte–machrophage lineage occurring in
the normal lung [63]. The origin of the expanded population of
LCs in the lungs is unknown. The increase of LCs may be due to
local proliferation of the cells but a more important mech-
anism is considered to be accumulation, through enhanced
recruitment of circulating precursors and delayed apoptosis
[69–72]. Recently, a report demonstrated that 50% of patients
with LC histiocytosis have a somatic mutation of the oncogene
BRAF, V600E. This observation strongly suggests that LC
histiocytosis is a neoplastic disease [73]. The presence of BRAF
V600E in PLCH was surprising considering the fact that 70% of
pulmonary diseases have been reported to be polyclonal; the
significance of this observation is not well understood. PLCH
probably represents a polyclonal reaction to cigarette smoking
in predisposed individuals [74]. Not surprising, many patients
with PLCH frequently show RB/DIP-like reactions in lung
biopsies. The disease affects young adults between 20 and 40 yrs
of age. No clear sex predominance of the disease has been
described. Patient’s presentation consists of dyspnoea, dry
cough and chest pain, as well as constitutional symptoms (fever,
malaise and weight loss) but the disease may be asymptomatic
(in ,25% of patients) [63, 65]. In the latter case, abnormal chest
radiographs are the only alterations and chest radiography is
performed for other reasons. Haemoptysis is an unusual
symptom in PLCH and should lead to investigations for an
alternative diagnosis or superimposed lung carcinoma in these
smoking patients. Measures of DL,CO are more sensitive in
detecting lung involvement than lung volumes measurements,
which could show normal, obstructive, restrictive or mixed
patterns [60, 75, 76]. A recent study shows that airway obs-
truction was the prevalent pattern of lung function defect
observed at diagnosis and during follow-up [77]. Cystic bone
lesions may be identified in ,10% of patients and may precede
the development of lung disease [60]. Diabetes insipidus and
skin lesions may be present [63]. Pneumothorax with chest pain
is the initial clinical presentation in 15% of patients with PLCH
and may be recurrent, requiring chest tube placement and
thoracotomy [78]. Pleurodesis is often required because of the
high rate of recurrence. Physical examination is usually indi-
fferent except in cases of pneumothorax. Pulmonary hyper-
tension is more prominent in advanced PLCH than in other
TABLE 1 Main histological lesions due to smoking and corresponding high-resolution computed tomography (HRCT) findings
Histology HRCT
Smoker’s macrophages within bronchiolar lumens and surrounding
alveolar spaces, mild bronchiolar fibrosis and inflammation
Hazy centrilobular nodules
Patchy ground-glass opacity
Mild distortion of bronchiolar lumens with bronchioloectasia and
mucostasis
Mild bronchial dilatation with wall thickening; mild air-trapping at expiratory
computed tomography scanning
Centrilobular and subpleural emphysema Centrilobular and paraseptal emphysema
Dense interstitial fibrosis, frequently surrounding
emphysematous holes
Peripheral and intralobular reticulation, ground-glass opacity intermingled with
emphysematous areas
Increase in Langerhans’ cells forming stellate bronchiolocentric
nodules, some of which are irregularly cavitated and fibrotic
Ill-defined or cavitated centrilobular nodules
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chronic lung diseases owing to direct intrinsic pulmonary
vascular/vasculitic involvement [79, 80]. PLCH has been
described in association with lung cancer as well as extra-
pulmonary cancers and lymphoma, especially Hodgkin disease
[67, 81, 82]. Neoplasms may be either synchronous with PLCH,
precede it or appear at another time. The occurrence of lung
cancer and other tobacco smoke-associated malignancies prob-
ably reflects the impact of smoking as a common aetiological
agent for each disease [67]. Prior treatment with chemother-
apeutic agents and chromosomal or genetic abnormalities are
factors that may confer a predisposition to the development of
malignant neoplasms in patients with PLCH. Clinical and
functional aspects of RB-ILD, DIP and PLCH in comparison
with CPFE are shown in table 2.
The role of BAL
BAL examination represents an important step in the diagnosis
of ILD [83]. In the majority of cases, the results of BAL fluid
examination only provide additional information and cannot
be used as the basis for definitive diagnosis of ILD. However,
this relatively noninvasive procedure is very useful in the
differential diagnosis of ILD; the normal cellular count of BAL
excludes active inflammation. The typical pathological features
in smoking-related ILD, RB-ILD and DIP is an important and
significant increase in total cells counts and in the number of
pigmented alveolar macrophages. The frequent observation in
DIP is an increase in the percentage of eosinophils and neu-
trophils. The BAL findings are not specific or diagnostic.
In PLCH the finding of .5% of LCs in BAL strongly suggests
the diagnosis in the appropriate clinical–radiological setting.
This cut-off distinguishes between patients with PLCH and
smokers without PLCH and other ILDs but reduces the test
sensibility [84, 85]. In our series of 27 patients with a diagnosis
of PLCH, bronchoscopic evaluation with BAL was performed
in 16 patients and BAL was diagnostic in four (25%) cases
(unpublished data). Our results are in agreement with data in
which a BAL sensitivity of ,25% is reported in PLCH diag-
nosis. In PLCH, a macrophagic alveolitis that reflects the
smoking history of the patients is typically present.
DIAGNOSTIC WORK-UP OF PATIENTS WITH
SUSPECTED SMOKING-RELATED ILDS
Diagnosis of RB-ILD and DIP
The diagnosis of RB-ILD is essentially a clinical-functional-
radiological-histological diagnosis and is based on global markers
of disease severity (symptoms, pulmonary functional impair-
ment and HRCT abnormalities), not on histological evaluation
in isolation. RB-ILD is histologically indistinguishable from RB
and RB is a very common, and possibly incidental, finding in
cigarette smokers. The discovery of RB on lung biopsy is not
equivalent to a diagnosis of RB-ILD. Since the clinical features of
RB-ILD may be confused with other ILDs and the imaging
TABLE 2 Clinical features of respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia
(DIP) and pulmonary Langerhans’ cell histiocytosis (PLCH) in comparison with combined pulmonary fibrosis and
emphysema (CPFE)
RB-ILD DIP PLCH CPFE
Smoking 100% 90% .90% 100% (heavy smokers)
Age 3rd to 5th decade 3rd to 5th decade 3rd to 4th decade 6th to 7th decade
Sex M:F Slight male dominance Nearly 2:1 1:1 Almost all male
Onset Insidious Insidious Insidious Insidious
Presenting symptoms Dyspnoea and cough Dyspnoea and cough Dyspnoea, cough and acute chest
pain (when pneumothorax is
present)
Dyspnoea and cough
Systemic involvement No Possible, rare Possible No
Crackles ,50% 60% Usually absent 87% basal
Clubbing Rare Nearly 50% Exceptional 43%
Pulmonary function Mixed defect or normal;
reduced DL,CO
Restrictive; reduced DL,CO Obstructive or restrictive; reduced
DL,CO (especially in patients with
vascular involvement)
Sub-normal pulmonary volumes;
severe reduction of DL,CO
Pulmonary hypertension No Rare Possible 47% at diagnosis; between 50%
and 90%
Desaturation on 6MWT No Possible Rare Frequent
Spontaneous improvement Possible Occasionally Possible No
Treatment Smoking cessation Smoking cessation and steroids Smoking cessation and steroids? Smoking cessation
Response to steroids Good Good Fair None
Prognosis Good Good Good Poor (5-yr survival is 55%)
Complete recovery possible Yes Yes Yes No
Correlation with lung cancer
or other neoplasms
No Rare Frequent Frequent (near 50%)
M: male; F: female; 6MWT: 6-min walk test; DL,CO: diffusing capacity of the lung for carbon monoxide.
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features overlap with other entities, such as hypersensitivity
pneumonitis, the diagnosis sometimes requires lung biopsy. In
the differential diagnosis between RB-ILD and hypersensitivity
pneumonitis, the history (RB-ILD occurs nearly only in smokers
whereas hypersensitivity pneumonitis is rare in smokers) and
BAL profile (macrophagic alveolitis is observed in RB-ILD and
lymphocytosis in hypersensitivity pneumonitis) are usually
definitive in distinguishing between these disorders. History,
HRCT and BAL findings usually allow diagnosis of RB-ILD
without the need for a lung biopsy. In the appropriate clinical–
radiological contest, a transbronchial biopsy that shows only the
characteristic aspects of RB may suggest the diagnosis of RB-
ILD. By contrast, lung biopsy is generally required to diagnose
DIP as the HRCT aspects of extensive ground-glass attenuation
and the highly cellular BAL profile are both nonspecific [18]. It is
important to remember that both DIP and RB-ILD are closely
related to cigarette smoking and their histological features may
be seen in association with other interstitial disease [4, 18, 41,
43]. DIP and RB-ILD should be diagnosed only in the absence of
aspects suggestive of other ILDs [4, 18, 41, 43]. Patients with DIP
may develop, in the long term, a HRCT pattern of fibrotic NSIP,
suggesting that NSIP could be considered a new smoking-
related interstitial lung disease [8]. However, the proposed
relationship of DIP to fibrotic NSIP remains uncertain. The
prognosis of DIP appears to be significantly better than that of
fibrotic NSIP, so while there can be morphological overlap
between the two, merging them into one disease may hide
important prognostic information [8].
Diagnosis of PLCH
The HRCT appearance in PLCH is diagnostic in most cases.
The simultaneous presence of multiple nodules, cavitated
nodules and cystic spaces with an upper lung predominance
and sparing of the lung bases in a young heavy smoker man is
characteristic of PLCH. In end-stage disease, when only diffuse
cysts with no nodules are present, the radiological diagnosis is
more difficult. BAL analysis may be useful if .5% of CD1a
cells are found, but this is more frequent in early stages of the
disease. In the presence of a radiological cystic lung disease,
macrophagic alveolitis on BAL examination may support the
diagnosis of PLCH. In case of another type of alveolitis in BAL,
the diagnosis should be reconsidered. In a small number of
cases, the diagnosis of PLCH may be obtained on transbron-
chial biopsy, in the presence of the appropriate clinical and
radiological setting [85, 86]. In our series of 27 patients with
PLCH, transbronchial biopsy was performed in three cases and
a diagnosis of PLCH was established in only one (33%) case
(unpublished data). Our limited data are consistent with the
literature where transbronchial biopsy is diagnostic in 10–40%
of cases. Confirmation of PLCH on transbronchial biopsy
requires a high index of suspicion and reliance on immuno-
histochemical demonstration of aggregates of LCs in the tissue
[86] or the recognition of stellate scars around the bronchioles.
The low diagnostic yield of transbronchial biopsy is partly due
to patchy distribution of the PLCH lesions and, in advanced
stages of disease, to the non-specificity of the histological
features, particularly in a small biopsy sample [67, 86]. In
clinical and/or radiological atypical cases, lung biopsy is
necessary for a definitive diagnosis. A confounding issue in the
diagnosis of PLCH by surgical lung biopsy is the exclusive
presence of end-stage fibrotic changes in which LCs are scare
or absent [87]. When this occurs, the diagnosis of PLCH may be
suggested based on the histological pattern of discrete
bronchiolocentric stellate scars with appropriate radiological
correlation. In lung biopsies of patients with PLCH one may
observe RB-/DIP-like changes as a consequence of pulmonary
injury associated with cigarette smoke and occasionally these
aspects may be sufficiently severe to cause ground-glass
attenuation on HRCT scanning and complicate the radiological
diagnosis [42].
TREATMENT AND PROGNOSIS
RB-ILD and DIP
Patients with RB-ILD usually do not need any specific treatment
other than smoking cessation. Progressive evolution to fibrotic
lung disease does not seem to occur and no deaths have been
attributed, with certainty, to RB-ILD [5, 11]. In case of pro-
gression of disease, steroids may be useful [88]. Spontaneous
improvement has been observed in some patients with DIP,
possibly related to smoke cessation. There is clinical deteriora-
tion in approximately two-thirds of patients with DIP who are
untreated [11, 89]. The mainstay of treatment in patients with
DIP consists of corticosteroid therapy, which may cause
stabilisation or improvement of the disease. Complete recovery
of the disease has been described [59, 89]. In ,25% of patients,
however, progression of disease may be observed despite
steroid therapy [11, 59, 89] and lung transplantation may be an
option. Recurrence has also been reported in patients who have
received a lung transplant [90].
PLCH
Smoking cessation leads to radiological improvement and even
complete recovery in early cellular and nodular cases of PLCH
[89, 91, 92]. The disease may improve with smoking cessation
alone; the 5- and 10-yr survival rate is 74.6% and 63.9%,
respectively [93]. There have been no randomised trials
comparing the efficacy of corticosteroids with that of smoking
cessation alone in PLCH, and it is therefore difficult to
establish the benefit of these two options. However, a subset
of patients experience progressive disease; in these cases
therapy still remains unsatisfactory and may include steroids
and/or cytotoxic agents (methotrexate, cyclophosphamide,
vinblastine, chlorambucil, etoposide and, 2-chlorodeoxy-
adenosine) [63, 66, 68]. Randomised trials valuating the efficacy
of each of these therapies are lacking. These drugs should be
reserved as salvage therapy for patients with progressive and
severe disease. Recently, 2-chlorodeoxyadenosine (cladribine)
was suggested as a promising treatment [94] and a randomised
trial is currently ongoing in symptomatic patients with lung
function impairment (www.clinicaltrials.gov NCT01473797).
Patients with progressive disease associated with severe respira-
tory impairment and who are unresponsive to steroid therapy or
chemotherapeutic agents should be considered for lung trans-
plantation [95]. Patients should stop smoking before lung
transplantation, as there is evidence of PLCH recurrence in the
transplanted lung if smoking is resumed [92]. The disease may
also recur in nonsmokers, especially in patients with extra-
pulmonary involvement [95]. The course of PLCH is variable and
difficult to predict in the single patient. Prognostic factors of the
disease are not well-known but obstruction, air-trapping and
reduced DL,CO on pulmonary function tests at diagnosis appear
to be helpful in identifying patients with a poor prognosis [96, 97].
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Other poor prognostic factors are older age at diagnosis and
corticosteroid therapy during follow-up [96, 97]. Severe pulmon-
ary hypertension is a frequent complication in patients with
advanced PLCH. Recent observations suggest that therapy
with bosentan [98] and other therapies utilised for idiopathic
pulmonary hypertension may be indicated in these patients
[99]. Fludeoxyglucose-positron emission tomography/computed
tomography images have been proposed as a new noninvasive
methodology for monitoring disease activity and response to
therapy [100, 101].
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